Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mease

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Annals of the Rheumatic Diseases|June 15, 2004
TNFalpha therapy in psoriatic arthritis and psoriasisP Mease
Clinical and Experimental Rheumatology|December 5, 2002
Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanerceptP Mease
Clinical and Experimental Rheumatology|January 16, 2010
The fibromyalgia conundrumP Mease, D Buskila, P Sarzi-Puttini
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis: epidemiology, clinical features, course, and outcomeD D Gladman, C Antoni, P Mease, et al.
Annals of the Rheumatic Diseases|June 20, 2014
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled studyA Kavanaugh, D Gladman, D van der Heijde, et al.
The British Journal of Dermatology|March 15, 2012
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extensionK Reich, J-P Ortonne, A B Gottlieb, et al.
RMD Open|January 27, 2017
Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritisD H Huynh, T A Boyd, C J Etzel, et al.
Annals of the Rheumatic Diseases|February 14, 2012
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexateP Mease, V Strand, L Shalamberidze, et al.
Clinical and Experimental Rheumatology|February 1, 2014
Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritisM H Favarato, P Mease, C R Gonçalves, et al.
Annals of the Rheumatic Diseases|January 17, 2009
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesG R Burmester, P Mease, B A C Dijkmans, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Annals of the Rheumatic Diseases|June 15, 2004
TNFalpha therapy in psoriatic arthritis and psoriasisP Mease
Clinical and Experimental Rheumatology|December 5, 2002
Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanerceptP Mease
Clinical and Experimental Rheumatology|January 16, 2010
The fibromyalgia conundrumP Mease, D Buskila, P Sarzi-Puttini
Annals of the Rheumatic Diseases|February 15, 2005
Psoriatic arthritis: epidemiology, clinical features, course, and outcomeD D Gladman, C Antoni, P Mease, et al.
Annals of the Rheumatic Diseases|June 20, 2014
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled studyA Kavanaugh, D Gladman, D van der Heijde, et al.
The British Journal of Dermatology|March 15, 2012
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extensionK Reich, J-P Ortonne, A B Gottlieb, et al.
RMD Open|January 27, 2017
Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritisD H Huynh, T A Boyd, C J Etzel, et al.
Annals of the Rheumatic Diseases|February 14, 2012
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexateP Mease, V Strand, L Shalamberidze, et al.
Clinical and Experimental Rheumatology|February 1, 2014
Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritisM H Favarato, P Mease, C R Gonçalves, et al.
Annals of the Rheumatic Diseases|January 17, 2009
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesG R Burmester, P Mease, B A C Dijkmans, et al.
Pageof 3